Drug Profile
Research programme: thymidylate synthase (TS) inhibitors - BTG PLC
Latest Information Update: 21 Aug 2019
Price :
$50
*
At a glance
- Originator BTG
- Class Small molecules
- Mechanism of Action Thymidylate synthase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 19 Aug 2019 BTG has been acquired by Boston Scientific Corporation
- 16 Jul 2016 No recent reports of development identified for preclinical development in Solid-tumours in United Kingdom
- 22 Feb 2008 Preclinical trials in Solid tumours in United Kingdom (unspecified route)